Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

Next Previous
Trial Profile

Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifapentine (Primary) ; Isoniazid; Rifampicin; Rifamycin
  • Indications Tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASTERoiD

Most Recent Events

  • 26 Sep 2024 Planned End Date changed from 1 Dec 2028 to 1 Dec 2029.
  • 26 Sep 2024 Planned primary completion date changed from 1 Dec 2028 to 1 Dec 2029.
  • 10 Jul 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top